Precipio, Inc. (PRPO) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Precipio, Inc. is a healthcare biotechnology company operating a single segment with two divisions: pathology services (clinical laboratory testing for hematologic cancers) and product development (proprietary diagnostic assay kits). The company utilizes its clinical laboratory operations as a self-funded R&D unit to validate diagnostic products.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Net Sales | $13,732 |
| Gross Profit | $5,861 |
| Gross Margin | 43% |
| Operating Loss | $(2,027) |
| Net Loss | $(1,662) |
| Cash Provided by Operating Activities | $724 |
| Cash and Cash Equivalents (Ending) | $3,075 |
| Working Capital | $2,836 |
| Total Debt (Current + Long-Term) | $325 |
| Accumulated Deficit | $(104,465) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 30% year-over-year (YoY) to $13.7 million, driven by a 42% increase in patient diagnostic cases processed (9,564 vs. 6,713).
- Expense Increases: Operating expenses rose 26% YoY to $7.9 million, primarily due to a $0.9 million increase in stock-based compensation and higher personnel costs for sales and R&D.
- Profitability: While gross profit increased 29% to $5.9 million, the company reported a net loss of $1.7 million compared to a net loss of $0.8 million in the prior year period. The widening loss was partially offset by non-recurring Employee Retention Credits (ERC) of $0.4 million.
- Cash Flow: Net cash provided by operating activities improved significantly to $0.7 million from $0.3 million in the prior year, aided by non-cash adjustments and working capital management.
Outlook, Risks, and Contingencies
- Going Concern: Management has disclosed substantial doubt about the company's ability to continue as a going concern for the next twelve months. This is due to an accumulated deficit of $104.5 million and reliance on achieving business plans or raising additional financing to meet debt obligations.
- Employee Retention Credits (ERC): The company received $0.4 million in ERC payments in the current period. Approximately $0.3 million remains outstanding from a prior claim, with no assurance of timing or receipt.
- Legal Proceedings: Two putative class action lawsuits were filed in April and May 2026 regarding a data security incident disclosed in December 2025. The cases have been consolidated, and the company is unable to estimate potential losses at this early stage.
- Cybersecurity Risk: The filing highlights significant risks related to the December 2025 cyberattack, including potential regulatory penalties, litigation costs, and reputational harm.
- Debt Obligations: The company holds a $0.3 million equipment loan (8.9% interest) and a $0.067 million DECD loan (3.25% interest).
Investor Verification Checklist
- Verify the timeline and likelihood of receiving the remaining $0.3 million in Employee Retention Credits.
- Monitor the status of the consolidated data security litigation and any potential settlement costs or regulatory fines.
- Assess the company's ability to secure additional financing given the "substantial doubt" going concern disclosure.
- Review the sustainability of the 42% increase in case volume and whether it can be maintained without further margin compression.
- Confirm the status of the $2.8 million in purchase commitments for reagents and the company's ability to fulfill them.